small molecule glp 1 agonist Figure from Drug Discovery at the Glucagon-Like Peptide-1 Receptor PDB-101: Molecule of the Month:

However, owing to the lack of consideration for brain capillary binding or sequestration, the reliability of these results regarding brain uptake pharmacokinetics has been questioned [21] as well as whether results could be translated into humans

Similarly the weight loss seen with Exenatide and some other early GLP-1 drugs was thought too limited to win approval for the treatment of obesity (Gilbert, Rosenthal, March 2024)

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

Additionally, abdominal visceral fat area, measured by computed tomography scan, was also significantly reduced in the semaglutide groups compared with the placebo group

37 19381943.( 10.2337/dc13-2618) [DOI] [PubMed] [Google Scholar] 27.Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S

However, due to the widespread presence of anti-PEG antibodies and PEG complement activation in vivo, peglosanatide is limited to the suitable population